1,905 Shares in Elevance Health, Inc. $ELV Purchased by Bridgefront Capital LLC

Bridgefront Capital LLC bought a new position in shares of Elevance Health, Inc. (NYSE:ELV) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 1,905 shares of the company’s stock, valued at approximately $616,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Advisors Capital Management LLC lifted its position in shares of Elevance Health by 15.2% in the 2nd quarter. Advisors Capital Management LLC now owns 1,331 shares of the company’s stock worth $518,000 after purchasing an additional 176 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Elevance Health by 4.5% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 55,412 shares of the company’s stock valued at $21,553,000 after buying an additional 2,374 shares during the period. Cetera Investment Advisers raised its stake in Elevance Health by 5.7% in the second quarter. Cetera Investment Advisers now owns 63,434 shares of the company’s stock worth $24,673,000 after buying an additional 3,438 shares in the last quarter. Intech Investment Management LLC raised its stake in Elevance Health by 12.3% in the second quarter. Intech Investment Management LLC now owns 27,790 shares of the company’s stock worth $10,809,000 after buying an additional 3,047 shares in the last quarter. Finally, Avantax Advisory Services Inc. lifted its holdings in Elevance Health by 9.4% during the second quarter. Avantax Advisory Services Inc. now owns 19,752 shares of the company’s stock worth $7,683,000 after buying an additional 1,694 shares during the period. Hedge funds and other institutional investors own 89.24% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on ELV shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $332.00 target price on shares of Elevance Health in a research report on Thursday, January 29th. Sanford C. Bernstein decreased their price objective on Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research note on Friday, January 30th. Wells Fargo & Company dropped their price objective on Elevance Health from $424.00 to $391.00 and set an “overweight” rating on the stock in a research report on Friday, January 30th. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, TD Cowen reiterated a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Twelve analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $387.40.

Elevance Health Stock Performance

Shares of ELV opened at $291.69 on Monday. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. The firm has a market cap of $64.38 billion, a PE ratio of 11.61, a P/E/G ratio of 1.61 and a beta of 0.51. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $458.75. The stock has a fifty day moving average price of $338.25 and a 200-day moving average price of $334.45.

Elevance Health (NYSE:ELV) last announced its earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. During the same period in the previous year, the business earned $3.84 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. Elevance Health’s payout ratio is presently 27.39%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.